Prostate Cancer

Prostate Cancer Risk After Single Negative Biopsy Quantified

Prostate Cancer Risk After Single Negative Biopsy Quantified

By

Men with a single negative prostate biopsy have a 20-year cumulative rate of prostate cancer diagnosis of 23.7%.

Online Calculator May Aid In Individualizing Prostate Cancer Care

Online Calculator May Aid In Individualizing Prostate Cancer Care

By

New tool promises to help patients decide whether radical prostatectomy or radiation therapy is their best treatment option.

Prednisone to Blame for ERA 223 Trial Failure?

Prednisone to Blame for ERA 223 Trial Failure?

By

The authors of a recent editorial offer an explanation for why radium-223 used in combination with abiraterone and prednisone did not lower the risk of symptomatic skeletal events and death among men with metastatic castration-resistant prostate cancer.

Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients

Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients

This survey assessed the opinions of oncologists, urologists, and oncology nurses on the use of shared decision-making in older men with metastatic castration-resistant prostate cancer.

Obesity Linked With Improved Survival in mCRPC

Obesity Linked With Improved Survival in mCRPC

By

Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found.

Radium-223 Use in mCRPC Differs By Race

Radium-223 Use in mCRPC Differs By Race

By

Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men.

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

By

Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found.

Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer

Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer

At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

By

By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

By

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

By

The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.

Newer mCRPC Drugs Led to Longer Survival in African American Patients

Newer mCRPC Drugs Led to Longer Survival in African American Patients

By

The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.

Darolutamide Improves Metastasis-Free Survival in CRPC

Darolutamide Improves Metastasis-Free Survival in CRPC

By

Median metastasis-free survival was longer with darolutamide than with placebo: 40.4 vs 18.4 months.

PCa Grade Group Better Predicts Pathologic Outcomes, Recurrence

PCa Grade Group Better Predicts Pathologic Outcomes, Recurrence

By

In a "real world" study, biopsy and surgical grade groups 2, 3, 4, and 5 each were associated with incrementally higher risks for adverse pathologic features and biochemical recurrence.

Guidelines for Germline Genetic Testing in PCa Insufficient

Guidelines for Germline Genetic Testing in PCa Insufficient

A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.

Prostate Cancer Active Surveillance Increasing in the US

Prostate Cancer Active Surveillance Increasing in the US

By

From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study.

Low Carb Diet + Walking May Ease ADT's Adverse Effects

Low Carb Diet + Walking May Ease ADT's Adverse Effects

By

In a small study, men on androgen deprivation therapy for prostate cancer lost weight and experienced improved hemoglobin A1C and lipid profiles.

Good Quality of Life Reported Even in Advanced Prostate Cancer

Good Quality of Life Reported Even in Advanced Prostate Cancer

By

Men with advanced disease report health-related quality of life similar to that of those with localized disease.

Study: Dialysis Is a Bigger Mortality Risk Than Some Cancers

Study: Dialysis Is a Bigger Mortality Risk Than Some Cancers

By

Compared with patients on maintenance dialysis, men with prostate cancer and women with breast cancer have better unadjusted 5-year survival probabilities.

First-Year Post-ADT Weight Loss Predicts Higher PCa Death Risk

First-Year Post-ADT Weight Loss Predicts Higher PCa Death Risk

By

Weight loss in the first year after starting androgen deprivation therapy in men who have undergone radical surgery for prostate cancer ups the risk of metastatic disease and death from prostate cancer.

Longer Androgen Suppression With RT Superior for Advanced PCa

Longer Androgen Suppression With RT Superior for Advanced PCa

By

Study finds 18 vs 6 months of androgen suppression and radiotherapy for locally advanced prostate cancer is associated with a 30% decreased risk of death from the disease.

Adding Docetaxel to ADT Not Beneficial in High-Risk PCa

Adding Docetaxel to ADT Not Beneficial in High-Risk PCa

By

In a study of men with nonmetastatic high-risk prostate cancer who have rising PSA after primary therapy, investigators found no significant difference in PSA progression-free survival.

Prostate Cancer ADT May Reduce Autoimmune Disease Risk

Prostate Cancer ADT May Reduce Autoimmune Disease Risk

By

Androgen deprivation therapy recipients had a significantly lower risk for autoimmune diseases overall and for Graves' disease, uveitis, and psoriasis.

Finasteride Not Tied to Increase in Prostate Cancer Mortality

Finasteride Not Tied to Increase in Prostate Cancer Mortality

Finasteride tied to lower risk for death from prostate cancer, but lower risk not statistically significant

Prostate Cancer Death Risk Linked to Post-EBRT Time to PSA Nadir

Prostate Cancer Death Risk Linked to Post-EBRT Time to PSA Nadir

By

Men with unfavorable-risk prostate cancer who had a detectable PSA nadir and a time to PSA nadir less than 12 months had a 5-fold increased risk of dying from their disease.

Prostate Cancer AS Can Be Safe for Men Younger Than 60

Prostate Cancer AS Can Be Safe for Men Younger Than 60

By

Five-year rates of biopsy progression-free, treatment-free, and cancer-specific survival are similar for men younger than 60 and those aged 60 and older when placed on active surveillance.

Fusion Biopsies in Prostate Cancer AS Predict Progression Risk

Fusion Biopsies in Prostate Cancer AS Predict Progression Risk

By

Negative findings on a confirmatory fusion biopsy are associated with a lower risk of Grade Group progression.

PCa Phenotype May Predict Response to Immune Checkpoint Blockade

PCa Phenotype May Predict Response to Immune Checkpoint Blockade

By

The MSI-H/dMMR phenotype in men with advanced PCa is associated with greater likelihood of a durable response to PD-1/PD-L1 inhibitors.

Suicide Risk Up More Than 4-fold for Cancer Patients

Suicide Risk Up More Than 4-fold for Cancer Patients

Standardized mortality ratio highest for cancers of lung, head and neck, testes, bladder, Hodgkin lymphoma.

Comorbidities Adversely Linked to Cancer Trial Participation

Comorbidities Adversely Linked to Cancer Trial Participation

Reduction in trial discussions, trial offers, trial participation seen with one or more comorbidities.

Renal and Urology News Articles

Sign Up for Free e-newsletters